Integrin Receptor Antagonists

Integrin Receptor Antagonist

Colitis, Ulcerative

Crohn Disease

Enteritis

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Vedolizumab, an integrin receptor antagonist, is a humanized IgG<span class="Sub">1 </span>monoclonal antibody produced in Chinese hamster ovary cells that binds to the human α4β7 integrin. ENTYVIO has an approximate molecular weight of 147 kilodaltons.</p><div class="Section" data-sectioncode="42229-5"><a name="section-9.1"></a><p></p><p class="First"><span class="Italics Underline">Intravenous ENTYVIO</span></p><p>ENTYVIO (vedolizumab) for injection is supplied as a sterile, white to off-white, preservative-free, lyophilized cake for intravenous infusion. After reconstitution with 4.8 mL Sterile Water for Injection, USP, 0.9% Sodium Chloride Injection, USP, or Lactated Ringer's Injection, USP, the resulting concentration is 60 mg/mL with a deliverable volume of 5 mL (300 mg) and the resulting pH is approximately 6.3.</p><p>Each single-dose vial contains 300 mg vedolizumab, arginine hydrochloride (131.7 mg), histidine (23 mg), histidine monohydrochloride (21.4 mg), polysorbate 80 (3 mg), and sucrose (500 mg).</p></div><div class="Section" data-sectioncode="42229-5"><a name="section-9.2"></a><p></p><p class="First"><span class="Italics Underline">Subcutaneous ENTYVIO</span></p><p>ENTYVIO (vedolizumab) injection is supplied as a sterile, clear to moderately opalescent, colorless to slightly yellow, preservative-free solution for subcutaneous administration.</p><p>Each single-dose prefilled syringe or single-dose prefilled pen (ENTYVIO PEN) contains 108 mg vedolizumab, arginine hydrochloride (17.77 mg), citric acid monohydrate (0.18 mg), histidine (3.86 mg), histidine monohydrochloride (1.86 mg), polysorbate 80 (1.35 mg), sodium citrate dihydrate (4.71 mg) and Sterile Water for Injection, USP, at a pH of 6.5.</p></div></section>

Entyvio

vedolizumab

vedolizumab 300 MG Injection

vedolizumab 300 MG Injection [Entyvio]

0.68 ML vedolizumab 159 MG/ML Prefilled Syringe

0.68 ML vedolizumab 159 MG/ML Prefilled Syringe [Entyvio]

0.68 ML vedolizumab 159 MG/ML Auto-Injector

0.68 ML vedolizumab 159 MG/ML Auto-Injector [Entyvio]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio is a medication used to reduce inflammation associated with moderate to severe ulcerative colitis or Crohn's disease. It specifically targets the gut, reducing systemic immunosuppressive effects. However, it may still increase the risk of infections.

Report Adverse Event 

Prescribing Information

Medication Guide 

Submit MSL Request

Pharmacy List 

Billing & Coding Guide 

Reimbursement Information

Reimbursement Guide 

Formulary Information

Infusion Center Finder

Coverage Authorization Request 

Coverage Authorization Appeals

Appeal Letter For Rejected Claim

Letter of Medical Necessity 

Entyvio Connect Enrollment Form 

Enroll in Patient Savings Program 

Co-Pay Claim Form 

Patient Assistance Application Form

Start Program [Awaiting Approval]

Bridge Program [Temporary loss or gap in coverage]

Other HCP Resources: Access Forms

Other HCP Resources: Peer Perspectives 

Other HCP Resources: Downloads

Patient Brochure

Patient Brochure- Spanish

Patient Infusion Guide 

Entyvio Connect Patient Brochure

Entyvio Connect Support Program 

Doctor Discussion Guide 

About Entyvio

Patient Stories 

Receiving Entyvio: Ulcerative Colitis 

Receiving Entyvio: Crohn's Disease

Patient Resources

Continuing Treatment - Traveling 

Instructions For Use: Ulcerative Colitis

Instructions For Use: Crohn's Disease